The pandemic has exacerbated already troubling trends in the market access but has also created an opportunity for change in how drugs are priced and procured.

Pharma is making great strides in tackling climate change, but more needs to be done to meet net zero targets.

Why is the purpose and value of medical affairs sometimes poorly understood by the wider pharma organisation, and what can be done?

In his second column, Davidek Herron, Global Head of Digital, Roche, considers this year’s successes and challenges and looks ahead to 2023.

While technology advances and mindsets shift, will there be space and demand for the role of the pharma sales reps in future?

The Japanese pharma industry has many intricacies, so how can companies navigate the ups and downs?

Daiichi Sankyo’s Mary Pinder-Schenck speaks about the evolution she has witnessed in oncology throughout her career and what she predicts for the future of the field.

A new review has outlined 20 recommendations for how the UK can become a world leader in cannabinoid innovation. But is it possible?